Showing results (101-110 of 119) with videos related to

Sort By:
Pageof 12
Advances in Therapy|May 23, 2026
First-Line Pembrolizumab Plus Chemotherapy for Advanced Biliary Tract Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-966 StudyZhenggang Ren, Tingbo Liang, Shanzhi Gu, et al.
Annals of Translational Medicine|April 3, 2023
Nomogram for tumour response based on prospective cohorts of hepatocellular carcinoma patients receiving immunotherapy combined with targeted therapy: development and validationQichen Chen, Yiqiao Deng, Chuanhua Zhao, et al.
Frontiers in Immunology|May 14, 2023
Systemic therapy with or without transcatheter intra-arterial therapies for unresectable hepatocellular carcinoma: a real-world, multi-center studyYangxun Pan, Xiaodong Zhu, Jianwei Liu, et al.
The Lancet. Oncology|September 13, 2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trialJordi Bruix, Tadatoshi Takayama, Vincenzo Mazzaferro, et al.
Liver Cancer|April 30, 2026
Integrated Multi-Omics Profiling Identifies an Immunotherapy Vulnerable and Prognostic Associated Subtype in CholangiocarcinomaLu Chen, Yuchao He, Hong Su, et al.
Lancet (London, England)|December 10, 2016
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trialJordi Bruix, Shukui Qin, Philippe Merle, et al.
Scientific Reports|April 28, 2024
Surgical treatment improves overall survival of hepatocellular carcinoma with extrahepatic metastases after conversion therapy: a multicenter retrospective studyXiaoshi Zhang, Xiaodong Zhu, Jianhong Zhong, et al.
The Oncologist|October 24, 2023
Prognoses of Patients Treated With Surgical Therapy Versus Continuation of Local-Plus-Systemic Therapy Following Successful Down-Staging of Intermediate-Advanced Hepatocellular Carcinoma: A Multicenter Real-World StudyJianwei Liu, Xiaodong Zhu, Yangxun Pan, et al.
Liver Cancer|May 26, 2025
Comparison of Efficacy between Lenvatinib and Bevacizumab in Combination of Immune Checkpoint Inhibitor and Interventional Triple Therapy in Chinese Advanced Hepatocellular Carcinoma: The CLEAP 2302 StudyZhaolong Pan, Dongming Liu, Junbo Cao, et al.
Alimentary Pharmacology & Therapeutics|June 23, 2023
Effect of different PD-1 inhibitor combination therapies for unresectable intrahepatic cholangiocarcinomaZhengqing Lei, Weihu Ma, Anfeng Si, et al.
Pageof 12